Oxaliplatin 50 mg/vial is a potent platinum-based chemotherapy drug used primarily in the treatment of colorectal cancer, especially in advanced stages or after surgical removal of the tumor. It contains the active substance oxaliplatin, which works by binding to the DNA in cancer cells, forming cross-links that inhibit DNA replication and transcription, ultimately leading to cell death. Oxaliplatin is often used as part of combination chemotherapy regimens such as FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), which has become a standard treatment for metastatic or adjuvant colon cancer therapy. It is administered by intravenous (IV) infusion, typically over a few hours, and the dosage and treatment cycles depend on the patient’s condition, response to therapy, and overall health.

Although effective, oxaliplatin can cause a number of side effects, the most common being nausea, vomiting, diarrhea, fatigue, and a distinctive cold-induced peripheral neuropathy—a nerve condition that causes tingling, numbness, or pain in the hands and feet, especially when exposed to cold. Other potential risks include low blood cell counts, which can increase the chance of infection or bleeding. Due to these effects, patients are closely monitored during treatment, with regular blood tests and supportive care to manage symptoms. Oxaliplatin should always be used under the guidance of an oncologist, and any side effects should be promptly reported to ensure safe and effective cancer treatment.